__NUXT_JSONP__("/drugs/Nilotinib_Hydrochloride_Monohydrate", (function(a,b,c){return {data:[{drug:{slug:a,emaEpar:[],fdaDrugLabel:[],id:a,nciThesaurus:{casRegistry:"923288-90-8",chebiId:"",chemicalFormula:"C28H22F3N7O.HCl.H2O",definition:"The monohydrate monohydrochloride form of nilotinib, an orally bioavailable aminopyrimidine-derivative Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity. Designed to overcome imatinib resistance resulting from Bcr-Abl kinase mutations, upon administration, nilotinib binds to and stabilizes the inactive conformation of the kinase domain of the Abl portion of the Bcr-Abl fusion protein, resulting in the inhibition of the constitutive kinase activity of Bcr-Abl protein. This inhibits the Bcr-Abl-mediated proliferation of Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) cells. Nilotinib also inhibits the receptor tyrosine kinases platelet-derived growth factor receptor (PDGF-R; PDGFR), mast\u002Fstem cell growth factor receptor Kit (c-Kit), and, to a lesser extent, colony-stimulating factor 1 receptor (CSF-1R; CSF1R), and discoidin domain-containing receptor 1 (DDR1).",fdaUniiCode:"5JHU0N1R6K",identifier:"C95229",preferredName:b,semanticType:"Pharmacologic Substance",subclassOf:["C155700","C159198","C159199"],synonyms:["4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]-benzamide, Monohydrochloride","AMN107","NILOTINIB HYDROCHLORIDE MONOHYDRATE",b,"Nilotinib Monohydrochloride Monohydrate","Tasigna"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FNilotinib_Hydrochloride_Monohydrate",extension:".json",createdAt:c,updatedAt:c}}],fetch:{},mutations:void 0}}("Nilotinib_Hydrochloride_Monohydrate","Nilotinib Hydrochloride Monohydrate","2021-10-30T13:47:57.333Z")));